Skip to main content

Advertisement

SpringerLink
Log in

The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Overexpression of cyclin-dependent kinase 1 (CDK1) has been noted to correlation with several human cancers. However, the effects of CDK1 on ovarian cancer development remain unclear. The aim of this study was to examine the effect of CDK1 and related mechanism in the proliferation and resistance to chemotherapeutic drugs of epithelial ovarian cancer (EOC). Immunohistochemical analysis was performed in 119 human ovarian cancer samples, and the data were correlated with clinicopathologic features. Furthermore, Western blot analysis was performed for CDK1 in EOC samples and cell lines to evaluate their protein levels and molecular interaction. Kaplan-Meier survival analysis showed that strong expression of CDK1 exhibited a significant correlation with poor prognosis in human EOC (P = 0.02). Meanwhile, we found that knockdown CDK1 by shCDK1 promoted the apoptosis rate and increased the sensitivity to chemotherapy drugs. Thus, CDK1 might serve as a prognostic marker, and it might be of great value for experimental therapies in EOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138.

    Article  PubMed  Google Scholar 

  2. Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2004;14(5):772–8. doi:10.1111/j.1048-891X.2004.014507.x.

    Article  CAS  Google Scholar 

  3. Leitao Jr MM, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, et al. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol. 2003;91(1):123–9.

    Article  CAS  PubMed  Google Scholar 

  4. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229–39. doi:10.1177/1758834014544121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Malumbres M. Physiological relevance of cell cycle kinases. Physiol Rev. 2011;91(3):973–1007. doi:10.1152/physrev.00025.2010.

    Article  CAS  PubMed  Google Scholar 

  6. Goranov AI, Amon A. Growth and division—not a one-way road. Curr Opin Cell Biol. 2010;22(6):795–800. doi:10.1016/j.ceb.2010.06.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66. doi:10.1038/nrc2602.

    Article  CAS  PubMed  Google Scholar 

  8. Li JM, Brooks G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Eur Heart J. 1999;20(6):406–20.

    Article  CAS  PubMed  Google Scholar 

  9. Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014;14:32. doi:10.1186/1471-2407-14-32.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kim SJ, Nakayama S, Shimazu K, Tamaki Y, Akazawa K, Tsukamoto F, et al. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2012;23(4):891–7. doi:10.1093/annonc/mdr340.

    Article  CAS  Google Scholar 

  11. Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer. 2012;106(1):133–40. doi:10.1038/bjc.2011.504.

    Article  CAS  PubMed  Google Scholar 

  12. Chang CC, Hung CM, Yang YR, Lee MJ, Hsu YC. Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells. J Ovarian Res. 2013;6(1):41. doi:10.1186/1757-2215-6-41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, et al. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011;122(3):641–7. doi:10.1016/j.ygyno.2011.05.003.

    Article  CAS  PubMed  Google Scholar 

  14. Yang Y, Ma B, Li L, Jin Y, Ben W, Zhang D, et al. CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumor-associated macrophages. Oncol Rep. 2014;31(6):2759–68. doi:10.3892/or.2014.3127.

    CAS  PubMed  Google Scholar 

  15. Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014;135(6):1286–96. doi:10.1002/ijc.28774.

    Article  CAS  PubMed  Google Scholar 

  16. Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem. 2014;289(13):9247–53. doi:10.1074/jbc.M114.551143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wu W, Ye H, Wan L, Han X, Wang G, Hu J, et al. Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo. Carcinogenesis. 2013;34(7):1636–43. doi:10.1093/carcin/bgt087.

    Article  CAS  PubMed  Google Scholar 

  18. Chen X, Zhang FH, Chen QE, Wang YY, Wang YL, He JC et al. The clinical significance of CDK1 expression in oral squamous cell carcinoma. Medicina oral, patologia oral y cirugia bucal. 2014.

  19. Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, et al. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS ONE. 2011;6(8):e23849. doi:10.1371/journal.pone.0023849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hedblom A, Laursen KB, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A, et al. CDK1 interacts with RARgamma and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle. 2013;12(8):1251–66. doi:10.4161/cc.24313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

A graduate project of the Science and Technology Innovation in Nantong University (YKS14023), contract grant number 13025202.

Conflicts of interest

None.

Author information

Author notes

    Authors and Affiliations

    1. Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu Province, China

      Qinghua Xi, Menghui Huang, Jianxin Zhong, Guiqin Xu, Lifei Jiang & Juan Wang

    2. Department of Pathology, Nantong University Cancer Hospital, Nantong University, 30. Tongyang North Road, Nantong, 226001, Jiangsu Province, China

      Shuyun Yang

    3. Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu Province, China

      Yingying Wang & Zheng Fang

    4. Department of Gynecologic Oncology, Nantong University Cancer Hospital, Nantong University, Nantong, 226001, Jiangsu Province, China

      Rong Liu

    Authors
    1. Qinghua Xi
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Menghui Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yingying Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Jianxin Zhong
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Rong Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Guiqin Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Lifei Jiang
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Juan Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Zheng Fang
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Shuyun Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Zheng Fang or Shuyun Yang.

    Additional information

    Qinghua Xi and Menghui Huang contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Xi, Q., Huang, M., Wang, Y. et al. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer. Tumor Biol. 36, 4939–4948 (2015). https://doi.org/10.1007/s13277-015-3141-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-3141-8

    Keywords

    Search

    Navigation